Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide.

Background: Abiraterone acetate (AA) and enzalutamide (ENZ) are oral therapies offering survival benefit to metastatic castration-resistant prostate cancer (mCRPC) patients. Despite the availability of multiple treatment options for mCRPC, there is a lack of information on the effect that being initiated on AA or ENZ has on the combined prostate cancer treatment duration.

Objective: To compare the combined duration of prostate cancer treatments of patients initiated on AA with that of patients initiated on ENZ.